Clear Search

Showing 3 results for “immunosuppression”.

October 2023

Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center

doi: 10.1177/09612033231204070 Epub ahead of print

Single-centre study concludes that adding belimumab to the standard of care treatment with mycophenolate (MMF) increases the possibility of achieving a complete clinical response (CCR), complete histological response (CHR), and a lower rate of relapses during treatment and long follow-up.

more…

June 2023

Remission of Lupus Nephritis: The Trajectory of Histological Response in Successfully Treated Patients

Lupus Sci Med. 2023;10(1):e000932 doi: 10.1136/lupus-2023-000932

LN histological activity takes months to years to resolve, providing a rationale for the need of long-term, well-tolerated maintenance immunosuppression.

more…

March 2022

Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis

Kidney Int Rep. 2021;7(3):516–25

Analysis of 22 patients with lupus nephritis (LN) demonstrates that triple immunosuppression with the addition of tacrolimus to mycophenolate and prednisolone results in further proteinuria reduction.

more…